SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Trend Setters and Range Riders
MSFT 478.74+0.1%2:49 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: bobby is sleepless in seattle who started this subject6/13/2001 1:45:18 PM
From: Frederick Langford  Read Replies (1) of 26752
 
IVX, Liking this generic...

IVAX Expects Second Quarter Earnings to Exceed Analysts' Expectations and

Anticipates Increased Paclitaxel Sales

Business Editors

MIAMI--(BUSINESS WIRE)--June 13, 2001--IVAX Corporation (AMEX:IVX)
expects that its second quarter earnings will exceed analysts'
expectations, based on preliminary results from operations for the
first two months of the quarter, together with sales made and expected
to be made during June. The First Call analyst consensus estimate for
IVAX is currently $.25 per share. IVAX plans to announce its second
quarter earnings near the end of July.
Financial results to date indicate that IVAX will have a strong
quarter and sales of IVAX' paclitaxel injection product are expected
to be greater than in the first quarter of 2001.
IVAX Corporation, headquartered in Miami, Florida, is engaged in
the research, development, manufacturing and marketing of branded and
brand equivalent pharmaceuticals and veterinary and diagnostic
products throughout the world...

A home towner

Fred
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext